score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Investigate Actionability - High	Clinical evidence		Clinical evidence	Somatic Variant	NRAS	Missense	p.Q61K	0.8272	382.0	0.0	0.0		Investigate Actionability - High	Selumetinib	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956							Investigate Actionability - High	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	254.0	0.9016	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	MEL-IPI_Pat98-Normal-SM-53U4K
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat98		
Investigate Actionability - Low	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability - Low	Infigratinib	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210												0				FGFR1 Deletion		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R147H	0.0811	37.0	0.0	0.0																			0	0.0	0.0	0.0	FLI1 p.R147H (Missense)		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	MEL-IPI_Pat98-Normal-SM-53U4K
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																			0				ESRP1 Amplification		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																			0				GATA3 Deletion		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Biologically Relevant				Copy Number	RET	Deletion				0.0	0.0																			0				RET Deletion		MEL-IPI_Pat98	MEL-IPI_Pat98-Tumor-SM-4CU6L	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification																							0				Supporting variants: ESRP1 Amplification		MEL-IPI_Pat98		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.932																							0				COSMIC Signature 1 (93%)		MEL-IPI_Pat98		
